Advertisement

Neurotoxicity Research

, Volume 22, Issue 1, pp 1–15 | Cite as

Rutin Protects Dopaminergic Neurons from Oxidative Stress in an Animal Model of Parkinson’s Disease

  • Mohd. Moshahid Khan
  • Syed Shadab Raza
  • Hayate Javed
  • Ajmal Ahmad
  • Andleeb Khan
  • Farah Islam
  • Mohammed M. Safhi
  • Fakhrul Islam
Article

Abstract

This study was undertaken to investigate the neuroprotective effects of rutin (vitamin P) on 6-hydroxydopamine (6-OHDA)-induced Parkinson’s disease (PD) in rats. Oxidative stress and inflammation is an important event, play a crucial role in neurodegenerative diseases. Rutin has been shown to have antioxidant and anti-inflammatory actions, and thus was tested for its beneficial effects using 6-OHDA-induced PD rat model. Male Wistar rats were pre-treated with rutin (25 mg/kg bwt, orally) for 3 weeks and subjected to unilateral intrastriatal injection of 6-OHDA (10 μg in 0.1% ascorbic acid in normal saline). Three weeks after 6-OHDA infusion, rats were tested for neurobehavioral activity, and were killed after 4 weeks of 6-OHDA infusion for the estimation of thiobarbituric acid reactive substances, glutathione, and its dependent enzymes (glutathione peroxidase and glutathione reductase), dopamine (DA) and its metabolite 3,4-dihydroxyphenyl acetic acid. The increase in 6-OHDA-induced rotations and deficits in locomotor activity and motor coordination and decrease in antioxidant level, DA content and its metabolite and increase in the number of dopaminergic D2 receptors in striatum were protected significantly with lesioned group pre-treated with rutin. These findings were further supported by the histopathological and immunohistochemical findings in the substantia nigra that showed that rutin protected neurons from deleterious effects of 6-OHDA. These results suggest that the consumption of rutin, which is novel vitamin, may have the possibility of protective effect against the neurological disorder such as PD.

Keywords

Rutin 6-Hydroxydopamine Behavioral activity Oxidative stress Inflammation Parkinson’s disease 

Notes

Acknowledgments

The authors thank the Department of Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy (AYUSH), Ministry of Health and Family Welfare, Government of India, New Delhi, for financial assistance. We greatly acknowledge Ms. Lorie Leo, Department of Internal Medicine, University of Iowa, for reviewing and editing this manuscript. Technical assistance of Dharamvir Singh is gratefully appreciated.

References

  1. Afanas’av IB, Dorozhko AI, Brodskii AV, Kostyuk VA, Potapovich AI (1989) Chelating and free radical scavenging mechanisms of inhibitory action of rutin and quercetin in lipid peroxidation. Biochem Pharmacol 38:1763–1769CrossRefGoogle Scholar
  2. Agrawal AK, Hussin R, Raghubir R, Kumar A, Seth PK (1995) Neurobehavioural, neurochemical and electrophysiological studies in 6-hydroxydopamine lesioned and neural transplanted rats. Int J Dev Neurosci 13:105–111PubMedCrossRefGoogle Scholar
  3. Ahmad M, Saleem S, Ahmad AS, Yousuf S, Ansari MA et al (2005) Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced Parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences. J Neurochem 93:94–104PubMedCrossRefGoogle Scholar
  4. Allbutt HN, Henderson JM (2007) Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson’s disease. J Neurosci Methods 159:195–202PubMedCrossRefGoogle Scholar
  5. Bishnoi M, Chopra K, Kulkarni SK (2007) Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. Fundam Clin Pharmacol 21:521–529PubMedCrossRefGoogle Scholar
  6. Blandini F, Armentero MT, Martignoni E (2008) The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord 14:S124–S129PubMedCrossRefGoogle Scholar
  7. Blum D, Torch S, Lambengm N, Nissou M, Benabid A, Sadoul R (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA. Dopamine and MPTP: contribution to apoptotic theory in Parkinson’s disease. Prog Neurobiol 65:135–172PubMedCrossRefGoogle Scholar
  8. Cannon JR, Keep RF, Hua Y, Richardson RJ, Schallert T, Xi G (2005) Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson’s disease model. Neurosci Lett 373:189–194PubMedCrossRefGoogle Scholar
  9. Carlberg I, Mannervik B (1975) Purification and characterization of the flavoenzyme glutathione reductase from rat liver. J Biol Chem 250:5475–5480PubMedGoogle Scholar
  10. Chaturvedi RK, Shukla S, Seth K, Chauhan S, Sinha C, Shukla Y, Agrawal AK (2006) Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease. Neurobiol Dis 22:421–434PubMedCrossRefGoogle Scholar
  11. Choi DK, Pennathur S, Perier C, Tieu K, Teismann P et al (2005) Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson’s disease in mice. J Neurosci 25:6594–6600PubMedCrossRefGoogle Scholar
  12. Claiborne A (1985) Catalase activity. In: Green Wald RA (ed) CRC hand book of methods for oxygen radical research. CRC Press, Boca Raton, FL, pp 283–284Google Scholar
  13. del Zoppo G, Ginis I, Hallenbeck JM, Iadecola C, Wang X, Feuerstein GZ (2000) Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol 10:95–112PubMedCrossRefGoogle Scholar
  14. Deumens R, Blokland A, Prickaerts J (2002) Modeling Parkinson’s disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175:303–317PubMedCrossRefGoogle Scholar
  15. Dringen R (2000) Metabolism and functions of glutathione in brain. Prog Neurobiol 62:649–671PubMedCrossRefGoogle Scholar
  16. Freeman BA, Crapo JD (1982) Biology of disease: free radicals and tissue injury. Lab Investig 47:412–426PubMedGoogle Scholar
  17. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM (2008) Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 28:7687–7698PubMedCrossRefGoogle Scholar
  18. Gupta R, Singh M, Sharma A (2003) Neuroprotective effect of antioxidants on ischaemia and reperfusion-induced cerebral injury. Pharmacol Res 48:209–215PubMedCrossRefGoogle Scholar
  19. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 8:382–397PubMedCrossRefGoogle Scholar
  20. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP (2003) The role of glial reaction and inflammation in Parkinson’s disease. Ann NY Acad Sci 991:214–228PubMedCrossRefGoogle Scholar
  21. Hirsch E, Hunot S, Hartmann A (2005) Neuroinflammatory processes in Parkinson’s disease. Parkinsonism Relat Disord 11:S9–S15PubMedCrossRefGoogle Scholar
  22. Ishrat T, Parveen K, Khan MM, Khuwaja G, Khan MB et al (2009) Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer’s type. Brain Res 1281:117–127Google Scholar
  23. Islam F, Zia S, Sayeed I, Zafar KS, Ahmad AS (2002) Selenium induced alteration on lipids, lipid peroxidation, and thiol group in circadian rhythm centers of rat. Biol Trace Elem Res 90:203–214PubMedCrossRefGoogle Scholar
  24. Jenner P (2003) Oxidative stress in Parkinson’s disease. Ann Neurol 53:S26–S36PubMedCrossRefGoogle Scholar
  25. Jenner P (2007) Oxidative stress and Parkinson’s disease. Handb Clin Neurol 83:507–520PubMedCrossRefGoogle Scholar
  26. Jiang ZY, Hunt JV, Wolff SP (1992) Ferrous ion oxidation in the presence of xylenol orange for detection of lipid hydroperoxide in low density lipoprotein. Anal Biochem 202:384–389PubMedCrossRefGoogle Scholar
  27. Jin F, Wu Q, Lu YF, Gong QH, Shi JS (2008) Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson’s disease in rats. Eur J Pharmacol 600:78–82PubMedCrossRefGoogle Scholar
  28. Joglar B, Rodriguez-Pallares J, Rodriguez-Perez AI, Rey P, Guerra MJ, Labandeira-Garcia JL (2009) The inflammatory response in the MPTP model of Parkinson’s disease is mediated by brain angiotensin: relevance to progression of the disease. J Neurochem 109:656–669PubMedCrossRefGoogle Scholar
  29. Jollow DJ, Mitchell JR, Zampaglione N, Gillette JR (1974) Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology 11:151–169PubMedCrossRefGoogle Scholar
  30. Kamalakkannan N, Prince PSM (2006) Rutin improves the antioxidant status in streptozotocin-induced diabetic rat tissues. Mol Cell Biochem 293:211–219PubMedCrossRefGoogle Scholar
  31. Khan MM, Ahmad A, Ishrat T, Khuwaja G, Srivastawa P, Khan MB et al (2009) Rutin protects the neural damage induced by transient focal ischemia in rats. Brain Res 1292:123–135PubMedCrossRefGoogle Scholar
  32. Kirik D, Rosenblad C, Bjorklund A (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 152:259–277PubMedCrossRefGoogle Scholar
  33. Koda T, Kuroda Y, Imai H (2008) Protective effect of rutin against spatial memory impairment induced by trimethyltin in rats. Nutr Res 28:629–634PubMedCrossRefGoogle Scholar
  34. Koda T, Kuroda Y, Imai H (2009) Rutin supplementation in the diet has protective effects against toxicant-induced hippocampal injury by suppression of microglial activation and pro-inflammatory cytokines: protective effect of rutin against toxicant-induced hippocampal injury. Cell Mol Neurobiol 29:523–531PubMedCrossRefGoogle Scholar
  35. Koprich JB, Reske-Nielsen C, Mithal P, Isacson O (2008) Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson’s disease. J Neuroinflammation 5:8PubMedCrossRefGoogle Scholar
  36. La Casa C, Villegas I, Alarcon De la Lastra C, Motilva V, Martin Calero MJ (2006) Evidence for protective and antioxidant properties of rutin, a natural flavone, against ethanol induced gastric lesions. J Ethnopharmacol 71:45–53CrossRefGoogle Scholar
  37. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG et al (1990) Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 186:464–478PubMedCrossRefGoogle Scholar
  38. Li Y, Hu X, Liu Y, Bao Y, An L (2009) Nimodipine protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. Neuropharmacology 56:580–589PubMedCrossRefGoogle Scholar
  39. Little JP, Villanueva EB, Klegeris A (2011) Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson’s disease. Mini Rev Med Chem 11:582–590PubMedCrossRefGoogle Scholar
  40. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275PubMedGoogle Scholar
  41. Meister A (1988) Glutathione metabolism and its selective modification. J Biol Chem 263:17205–17208PubMedGoogle Scholar
  42. Misko TP, Schilling RJ, Salvemini D, Moore WM, Currie MG (1993) A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem 214:11–16PubMedCrossRefGoogle Scholar
  43. Mogi M, Togari A, Tanaka K, Ogawa N, Ichinose H, Nagatsu T (1999) Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-dopa on the TNF-alpha induction. Neurosci Lett 268:101–104PubMedCrossRefGoogle Scholar
  44. Mohandas J, Marshall JJ, Duggin GG, Horvath JS, Tiller D (1984) Differential distribution of glutathione and glutathione related enzymes in rabbit kidneys: possible implication in analgesic neuropathy. Cancer Res 44:5086–5091PubMedGoogle Scholar
  45. Ogura T, Ogata M, Akita H, Jitsuki S, Akiba L, Noda K et al (2005) Impaired acquisition of skilled behaviour in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson’s disease. Neurosci Res 51:299–308PubMedCrossRefGoogle Scholar
  46. Paxinos G, Watson C (1982) The rat brain in stereotaxic coordinates, 4th ed. Academic Press, San Diego, CAGoogle Scholar
  47. Pu F, Mishima K, Egashira N, Iwasaki K, Kaneko T, Uchida T et al (2004) Protective effect of buckwheat polyphenols against long-lasting impairment of spatial memory associated with hippocampal neuronal damage in rats subjected to repeated cerebral ischemia. J Pharmacol Sci 94:393–402PubMedCrossRefGoogle Scholar
  48. Pu F, Mishima K, Irie K, Motohashi K, Tanaka Y, Orito K et al (2007) Neuroprotective effects of quercetin and rutin on spatial memory impairment in an 8-arm radial maze task and neuronal death induced by repeated cerebral ischemia in rats. J Pharmacol Sci 104:329–334PubMedCrossRefGoogle Scholar
  49. Rozas G, Lopez-Martin E, Guerra MJ, Labandeira-Garcia JL (1998) The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods 83:165–175PubMedCrossRefGoogle Scholar
  50. Sánchez-Iglesias S, Méndez-Alvarez E, Iglesias-González J, Muñoz-Patiño A, Sánchez-Sellero I, Labandeira-García JL et al (2009) Brain oxidative stress and selective behaviour of aluminium in specific areas of rat brain: potential effects in a 6-OHDA-induced model of Parkinson’s disease. J Neurochem 109:879–888PubMedCrossRefGoogle Scholar
  51. Sauer H, Oertel WH (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59:401–415PubMedCrossRefGoogle Scholar
  52. Schwarting RKW, Hudson JL (1996) The unilateral 6-OHDA injection lesion model in behaviour brain research: analysis of functional deficit, recovery and treatment. Prog Neurobiol 50:275–331PubMedCrossRefGoogle Scholar
  53. Stevens M, Obrosova I, Cao X, Huysen CV, Green DA (2000) Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism and oxidative stress in experimental diabetic neuropathy. Diabetes 49:1006–1015PubMedCrossRefGoogle Scholar
  54. Sun Y (1990) Free radicals, antioxidant enzymes and carcinogenesis. Free Rad Biol Med 8:583–599PubMedCrossRefGoogle Scholar
  55. Tansey MG, McCoy MK, Frank-Cannon TC (2007) Neuroinflammatory mechanisms in Parkinson’s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 208:1–25PubMedCrossRefGoogle Scholar
  56. Utely HC, Bernheim F, Hochslein P (1967) Effect of sulfhydryl reagent on peroxidation in microsome. Arch Biochem Biophys 260:521–531Google Scholar
  57. Xue YQ, Zhao LR, Guo WP, Duan WM (2007) Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioural outcome in a rat model of Parkinson’s disease. Neuroscience 146:1245–1258PubMedCrossRefGoogle Scholar
  58. Zafar KS, Siddiqui A, Sayeed I, Ahmad M, Salim S, Islam F (2003) Dose-dependent protective effect of selenium in rat model of Parkinson’s disease: neurobehavioural and neurochemical evidences. J Neurochem 84:438–446PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Mohd. Moshahid Khan
    • 1
    • 3
  • Syed Shadab Raza
    • 1
  • Hayate Javed
    • 1
  • Ajmal Ahmad
    • 1
    • 4
  • Andleeb Khan
    • 1
  • Farah Islam
    • 2
  • Mohammed M. Safhi
    • 5
  • Fakhrul Islam
    • 1
    • 5
  1. 1.Neurotoxicology Laboratory, Department of Medical Elementology & ToxicologyJamia Hamdard (Hamdard University)New DelhiIndia
  2. 2.Department of BiotechnologyFaculty of Pharmacy, Jamia Hamdard (Hamdard University)New DelhiIndia
  3. 3.Department of Neurology, Carver College of MedicineUniversity of IowaIowaUSA
  4. 4.Department of NeurologyGeorgia Health Science UniversityAugustaUSA
  5. 5.Neuroscience and Toxicology Unit, Faculty of PharmacyJazan UniversityGizanKingdom of Saudi Arabia

Personalised recommendations